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Abstract
 
Myeloid progenitor cells give rise to a variety of progenies including dendritic cells. However,
the mechanism controlling the diversification of myeloid progenitors into each progeny is largely
unknown. PU.1 and CCAAT/enhancing binding protein (C/EBP) family transcription factors
have been characterized as key regulators for the development and function of the myeloid sys-
tem. However, the roles of C/EBP transcription factors have not been fully identified because of
functional redundancy among family members. Using high titer–retroviral infection, we dem-
onstrate that a dominant-negative C/EBP completely blocked the granulocyte–macrophage
commitment of human myeloid progenitors. Alternatively, Langerhans cell (LC) commitment
 
was markedly facilitated in the absence of tumor necrosis factor (TNF)
 

 
, a strong inducer of LC
development, whereas expression of wild-type C/EBP in myeloid progenitors promoted granu-
locytic differentiation, and completely inhibited TNF
 

 
-dependent LC development. On the
other hand, expression of wild-type PU.1 in myeloid progenitors triggered LC development in
the absence of TNF
 

 
, and its instructive effect was canceled by coexpressed C/EBP. Our find-
ings establish reciprocal roles for C/EBP and PU.1 in LC development, and provide new insight
into the molecular mechanism of LC development, which has not yet been well characterized.
Key words: myeloid differentiation • lineage commitment • dendritic cells • eosinophils • 
dominant-negative C/EBP
 
Introduction
 
The hematopoietic system is maintained by the continuous
proliferation and differentiation of progenitor cells gener-
ated from the pluripotent hematopoietic stem cells (1).
Among lineage-committed progenitor cells, myeloid pro-
genitors give rise to a variety of progenies, such as granulo-
cytes, monocytes/macrophages, osteoclasts, mast cells, and
dendritic cells. However, the mechanism controlling the
diversification of myeloid progenitor cells into each myeloid
progeny is largely unknown. Transcriptional regulation is a
key step in this process and myeloid-specific transcriptional
regulatory factors establish gene expression programs that
are intrinsic to cell diversification (2). Several transcription
factors have been implicated in this process, including PU.1,
 
CCAAT/enhancer binding protein (C/EBP)
 
*
 
 family (2),
IFN consensus sequence binding protein (3), JunB (4), and
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MafB (5). Among them, PU.1 and C/EBP family proteins
have been characterized as key regulators for the develop-
ment and function of the myeloid system (2).
PU.1 is a member of the Ets transcription family whose
expression is confined to hematopoietic cells. PU.1
mRNA is detectable even in multipotent hematopoietic
stem cells and is up-regulated during myeloid and B cell
differentiation. A large number of PU.1 target genes have
been identified in myeloid cells (2, 6), indicating that PU.1
plays important roles at various stages of myeloid differen-
tiation. Loss of function experiments revealed that in gen-
eral PU.1 is essential for the development of myeloid and
B cells (7, 8).
C/EBP proteins comprise a family of transcription fac-
tors that have a basic region-leucine zipper (bZIP) structure
consisting of a DNA-binding basic region and a leucine
zipper dimerization domain (9). All of the members of this
family (C/EBP
 

 
, C/EBP
 

 
, C/EBP
 

 
, C/EBP
 

 
, C/EBP
 

 
,
and C/EBP
 

 
) share the highly conserved dimerization do-
main, by which they homodimerize or heterodimerize
each other and bind to the cognate C/EBP consensus se-
quences. Among them, C/EBP
 

 
, C/EBP
 

 
, C/EBP
 

 
, and
C/EBP
 

 
 have a transcriptional activation domain and co-
operatively activate the transcription of a variety of my-
eloid-specific genes with PU.1. On the other hand,
C/EBP
 

 
 lacks the transcriptional activation domain and at-
tenuates transcriptional activation of target genes through
heterodimerizing with other family members, suggesting its
dominant-negative characteristics. C/EBP
 

 
 also works in a
dominant-negative fashion because its unique structure of
DNA-binding region prevents heterodimer binding to the
classic C/EBP consensus sequences. C/EBP proteins con-
trol the transcription of genes involved in a broad range of
physiological processes, including the development and
function of hematopoietic cells, adipocytes, and hepato-
cytes (9). In the hematopoietic system, C/EBP
 

 
, C/EBP
 

 
,
C/EBP
 

 
, and C/EBP
 

 
 are preferentially expressed in my-
eloid lineage, whereas the expression of C/EBP
 

 
 and
C/EBP
 

 
 is ubiquitous. The overlapping expression of
C/EBP members suggests that myeloid development and
functions are regulated by various combinations of C/EBP
homodimers and heterodimers. In this process, it is be-
lieved that there is a functional redundancy among C/EBP
 

 
,
C/EBP
 

 
, C/EBP
 

 
, and C/EBP
 

 
, and that they could
functionally compensate each other (10). Recent work
with mice that are genetically altered to abolish the expres-
sion of C/EBPs, underscore the role of these factors in the
myeloid system. Knockout mice of the C/EBP
 

 
 gene
show a selective block in the differentiation of granulo-
cytes, including both neutrophils and eosinophils (11). In
contrast, C/EBP
 

 
 knockout mice show impaired terminal
differentiation and defective function of granulocytes, both
of which cause susceptibility to fatal infection (12). These
results strongly suggest a critical role of C/EBP
 

 
 and
C/EBP
 

 
 in granulocytic differentiation. C/EBP
 

 
 knock-
out mice, however, do not show any defects in myeloid
differentiation; instead, the macrophage function is pro-
foundly impaired (13). In C/EBP
 

 
 knockout mice, my-
 
eloid cells are virtually intact (14). So far, no information is
available on myeloid cells in C/EBP
 

 
 and C/EBP
 

 
 knock-
out mice, although NK cell function is affected in C/EBP
 

 
knockout mice (15). Given the functional redundancy among
C/EBP members whose expression is highly overlapping in
myeloid cells, single-gene knockout mice do not unveil all
the physiological roles of C/EBP family members. Func-
tional redundancy has been partially canceled by making
double knockout mice of C/EBP
 

 
 and C/EBP
 

 
 genes in
terms of adipocyte differentiation (14).
Dendritic cells (DC) are the most effective type of anti-
gen-presenting cells and are characterized by an excep-
tional ability to stimulate naive T cell responses, as well as
B cell responses. Presently, two distinct types of DC, my-
eloid and lymphoid, are known (16). In human bone mar-
row, immature DC originate from CD34
 

 
 hematopoietic
progenitor cells and are seeded via the bloodstream to the
tissues where they capture and process antigens. Displaying
large amounts of MHC–peptide complexes at their surface,
they migrate to lymphoid organs where they activate anti-
gen-specific T cells. There are two discrete populations of
myeloid DC: Langerhans cells (LC) and dermal or intersti-
tial DC (16). Bone marrow CD34
 

 
 hematopoietic progen-
itor cells contain progenitors for both populations. The LC
progenitors express cutaneous lymphocyte antigen, lack
CD14, and cannot differentiate into macrophages. In con-
trast, the dermal DC progenitors lack cutaneous lympho-
cyte antigen, give rise to CD14
 

 
 monocytes, and differen-
tiate into either macrophages in response to M-CSF, or
DC in response to GM-CSF and IL-4, or TNF
 

 
 (17, 18).
LC are specialized DC that are present in the epidermis,
bronchi, and mucosae. Mice that are deficient in TGF
 

 
show selective absence of epidermal LC (19). On the other
hand, mice with a dominant-negative mutation of the
Ikaros gene lack all DCs except for LC (20), whereas RelB
knockout mice selectively lack CD8
 

 
	
 
 myeloid DC, but
retain LC (21). These findings indicate the specialized de-
velopment of LC from bone marrow progenitor cells.
To further understand the roles of C/EBP transcription
factors in myeloid development, we tried to disrupt the
functional redundancy among C/EBP family members by
expressing a dominant-negative C/EBP that could antago-
nize all C/EBP members. The expression of a dominant-
negative C/EBP completely blocked both granulocyte and
monocyte/macrophage development from CD34
 

 
 he-
matopoietic progenitor cells, and instead facilitated LC de-
velopment. Conversely, C/EBP transcription factors were
shown to be inhibitory to LC development induced by cy-
tokines, whereas another myeloid transcription factor,
PU.1, positively regulated LC development. Our findings
establish novel roles of C/EBP and PU.1 transcription fac-
tors in LC development.
 
Materials and Methods
 
Production of Retrovirus.
 
The retroviral vector pGCsam, with
an LTR derived from murine stem cell virus (MSCV), has intact
splice–donor and splice–acceptor sequences for the generation of
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subgenomic mRNA (22). A dominant-negative form of C/EBP
(A-C/EBP), followed by IRES enhanced green fluorescent pro-
tein (EGFP) and mouse PU.1 cDNA, followed by ires nerve
growth factor receptor (NGFR) truncated in the cytoplasmic do-
main, were subcloned into pGCsam. Human C/EBP
 

 
 and
C/EBP
 

 
 followed by ires EGFP were subcloned into pMSCV, a
retroviral vector with an LTR derived from MSCV. Human
C/EBP
 

 
 mutants, 
 


 
bZIP (
 


 
282–358) tagged with nuclear local-
ization signals from SV40 large-T antigen, and 
 


 
AD (
 


 
1–174)
were generated by PCR and tagged with a FLAG epitope at the
NH
 
2 
 
terminus. These mutants, followed by IRES EGFP, were
similarly subcloned into pMSCV. To produce the recombinant
retrovirus, plasmid DNA was transfected into 293 gp cells (293
cells containing the 
 
gag
 
 and 
 
pol
 
 genes but lacking an envelope
gene), along with 10A1 
 
env
 
-expressed plasmid (pCL-10A1)(23)
by CaPO
 
4
 
 coprecipitation and supernatant from the transfected
cells was collected to infect cells. 293 gp cells were supplied by
Nikunj Somia (University of Minnesota, Minneapolis, MN). 
 
Purification of Human Primary Cells.
 
Human umbilical cord
blood samples were obtained with informed consent from pla-
centas of full term, normal newborn infants. Cord blood was sup-
plied by Yoshihiro Shiina (Shiina Hospital, Ushiku, Ibaraki, Japan).
Peripheral blood samples were obtained from normal healthy vol-
unteers who had given informed consent. After the isolation of
mononuclear cells by density-gradient centrifugation, CD34
 

 
 he-
matopoietic progenitors and CD14
 

 
 monocytes were obtained
using magnetic bead separation (Miltenyi Biotec). In all experi-
ments, 
 

 
95% of purified cells were positive for CD34 or CD14,
as judged by specific antibodies (22).
 
Transduction of CD34
 

 
 Cells.
 
CD34
 

 
 cells were prestimu-
lated in IMDM (Sigma-Aldrich) supplemented with 10% fetal
bovine serum (FBS), 50 ng/ml stem cell factor (SCF), 50 ng/ml
thrombopoietin (provided by KIRIN), 50 ng/ml IL-6 (Pepro-
Tech), and 25 ng/ml Flt-3 ligand (PeproTech) for 20 h. After re-
plating onto recombinant fibronectin fragment-coated culture
dishes (Takara Shuzo Co.) containing virus supernatant and 5
 

 
g/ml protamine sulfate (Sigma-Aldrich), cells were centrifuged
at 1,000 
 
g
 
 for 30 min. Transduction was repeated three times
with fresh virus supernatant every 12 h. 60 h after the first trans-
duction, NGFR- or EGFP-positive cells were selected by cell
sorting on a FACSVantage
 
®
 
 (Becton Dickinson) and subjected to
subsequent analyses. At this time point, 
 

 
85% of the cells were
still positive for CD34 (22). To detect the expression of NGFR
truncated in the cytoplasmic domain on the cell surface, cells
were stained with mouse anti-human NGFR (CHEMICON)
followed by PE-conjugated rabbit anti–mouse Igs (Dako).
 
Colony Assay and In Vitro Liquid Culture.
 
CD34
 

 
 cells trans-
duced with the indicated retrovirus were plated in methylcellu-
lose medium (StemCell Technologies, Inc.) or cultured in
IMDM with 10% FBS. Cytokines were supplemented to culture
at the concentrations of 50 ng/ml SCF, G-CSF, GM-CSF,
M-CSF, IL-3, and 5 U/ml erythropoietin. The culture dishes
were incubated at 37
 

 
C in a 5% CO
 
2
 
 atmosphere. Colony num-
bers were counted at day 14. To check the development of IL-5–
responsive eosinophils, transduced cells were cultured in the pres-
ence of SCF, IL-3, and GM-CSF for the first 5 d. Then, cells
were incubated in the presence of 50 ng/ml of IL-5 alone.
 
Generation of DC.
 
CD34
 

 
 cells transduced with the indicated
retrovirus were cultured in IMDM supplemented with 10% FBS,
and 50 ng/ml SCF, GM-CSF, and TNF
 

 
 (PeproTech) at 37
 

 
C
in a 5% CO
 
2
 
 atmosphere. To assess the frequency of DC colony
formation, transduced cells were sorted into 96-well round-bot-
tomed plates (Corning) at 10 cells per well and cultured under the
 
conditions described above. Peripheral blood CD14
 

 
 monocytes
were cultured in IMDM supplemented with 10% FBS, and 50
ng/ml of GM-CSF and IL-4 (PeproTech) for 10 d. To activate
monocyte-derived DCs, 50 ng/ml TNF
 

 
 was added to the cul-
ture for the last 3 d.
 
Cell Surface Analysis.
 
Expression of cell surface antigens was
analyzed on a FACSVantage
 
®
 
. Cells were stained with APC-con-
jugated anti-human CD11b (BD Pharmingen) and CD14 (Im-
munotech); PE-conjugated anti-human CD1a, CD15 (Immu-
notech), CD14, CD40, and HLA-DR (BD Pharmingen);
biotinylated anti-human CD80 and CD86 (BD Pharmingen),
followed by PE-conjugated streptavidin (BD Pharmingen); and
unconjugated anti-human Langerin (Immunotech) and E-cad-
herin (R&D Systems), followed by PE-conjugated rabbit anti–
mouse Igs (Dako). Cells that became marked with propidium io-
dide were gated out as dead.
 
Reverse Transcription (RT)-PCR.
 
After the isolation of mono-
nuclear cells, cord blood CD34
 

 
 cells and peripheral blood
CD14
 

 
 monocytes were purified by cell sorting on a FACSVan-
tage
 
®
 
. DCs were generated from cord blood CD34
 

 
 cells and pe-
ripheral blood CD14
 

 
 monocytes as described above, and then
CD1a
 

 
 DCs were purified by cell sorting. The total RNA was
isolated from sorted cells using ISOGEN-LS solution (Nippon
Gene), and reverse-transcribed using ThermoScript RT-PCR
system (GIBCO BRL) and oligo-dT primer. The amount of
cDNA was normalized by the quantitative PCR using TaqMan
rodent GAPDH control reagent (PerkinElmer). Semiquantitative
RT-PCR reactions were then performed for 35 cycles using nor-
malized cDNAs and recombinant Taq DNA polymerase. The
cycling parameters were denaturation at 94
 

 
C for 20 s, annealing
at 60
 

 
C for 20 s, and extension at 72
 

 
C for 30 s. PCR products
were separated on agarose gel and visualized by ethidium bro-
mide staining. The primer sequences were: C/EBP
 

 
 sense
primer 5
 

 
-AAGGTGCTGGAGCTGACCAG-3
 

 
; antisense
primer 5
 

 
-AATCTCCTAGTCCTGGCTCG-3
 
, C/EBP
sense primer 5-ACAGCGACGAGTACAAGATCC-3; anti-
sense primer 5-GCAGCTGCTTGAACAAGTTCC-3, C/EBP
sense primer 5-ATGGATCGAAACAGTGACGAG-3; anti-
sense primer 5-TCAGTGCTAATGGACTGTACG-3, C/EBP
sense primer 5-ACATAGGAGCGCAAAGAAGC-3; antisense
primer 5-GCTTTATTCTTACAAATACTG-3, C/EBP sense
primer 5-AGTCTGGGGAAGAGCAGCTTC-3; antisense
primer 5-ACAGTGTGCCACTTGGTACTG-3, C/EBP
sense primer 5-TACCTATGTTTCACCTCCTGG-3; anti-
sense primer 5-ATTCTCTTCAGCTAGCTGTGC-3, PU.1
sense primer 5-ATGTGCCTCCAGTACCCATC-3; and anti-
sense primer 5-TCTTCTGGTAGGTCATCTTC-3.
Allogenic T Cell Proliferation (MLR). Allogenic CD4 T cells
were purified from cord blood cells using magnetic bead separa-
tion (Miltenyi Biotec). In all experiments, 95–97% of purified
cells were positive for CD4 as judged by a specific antibody.
CD34 cells, transduced with the indicated retrovirus, were cul-
tured in the DC condition for 10 d and used as stimulator cells. A
constant number of 105 allogenic CD4 T cells (responder) were
incubated with graded numbers of irradiated (3,000 rad, 137Cs
source) stimulators. The experiments were performed in 96-well
flat-bottomed plates (Corning) in RPMI 1640 (Sigma-Aldrich)
supplemented with 10% FBS. The proliferation of T cells was
monitored by measuring BrdU (5-bromo-2-deoxyuridine) in-
corporation (Boehringer) on day 4 of culture. Cells were har-
vested for 16 h after the addition of BrdU. BrdU incorporation
was assessed by absorbance at a wavelength of 370 nM using a
multiwell ELISA reader.
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Cytochemical Analysis. Cells were cytocentrifuged onto glass
slides and were stained by May-Grüenwald Giemsa staining. To
detect eosinophil peroxidase (EPO) expression, permeabilized
cytospun cells were stained with anti-human EPO (BD Pharmin-
gen), followed by EnVision-labeled polymer/alkaline phos-
phatase (Dako). 
Development of Cell Lines Expressing A-C/EBP. U937 cells
were transfected with a linealized human methallothionein pro-
moter (24), driving A-C/EBP expression by electroporation and
selected by G418. We isolated several U937/A-C/EBP clones
that induced a high level of A-C/EBP protein after treatment
with 100 M ZnSO4. Monocytic differentiation of U937 cells
was induced with 50 ng/ml human GM-CSF.
Western Blotting. Cells were solubilized with lysis buffer (50
mM Tris [pH 8.0], 1% Triton X-100, 0.5% sodium deoxycho-
late, 0.1% SDS, 5 mM EDTA, 150 mM sodium chloride, 50 g/
ml aprotinin, and 1 mM PMSF), and then lysates were resolved
by SDS-PAGE and transferred to a polyvinylidene difluoride
membrane. The membrane was probed with biotinylated anti-
FLAG antibody (Sigma-Aldrich), followed by streptavidin-HRP
(Amersham Pharmacia Biotech).
Results
A Dominant-negative C/EBP Switches Myeloid Cell Fate
from Granulocytes/Macrophages to LCs. To disrupt the func-
tional redundancy among C/EBP family members in my-
eloid cells, we adopted a dominant-negative C/EBP that
potentially antagonizes all C/EBP members. The domi-
nant-negative C/EBP, designated as A-C/EBP, is a 102–
amino acid protein consisting of an amino-terminal 9–amino
acid FLAG epitope, a 13–amino acid linker, a 31–amino
acid–designed acidic amphipathic helix, and a 49–amino acid
leucine zipper domain of C/EBP (25). The leucine zipper
from C/EBP specifically interacts with endogenous
C/EBP leucine zippers, whereas the NH2-terminal acidic
extension forms a coiled coil with endogenous C/EBP
basic regions. This heterodimeric coiled coil structure is
much more stable than C/EBP bound to DNA and causes
the dominant-negative protein to abolish DNA binding of
endogenous C/EBP family members.
By using a retrovirus-mediated gene transfer system, we
expressed A-C/EBP in human cord blood CD34 progen-
itor cells and analyzed its effects on myelopoiesis. We trans-
duced cells with the retroviral vector GCsam–A-C/EBP–
internal ribosome entry site (IRES)–EGFP (Fig. 1 A),
which drives expression of both A-C/EBP and EGFP from
a single bicistronic message. After transduction, EGFP-pos-
itive cells were selected by cell sorting and subjected to in
vitro assay. Among various kinds of cytokines, CD34 pro-
genitors expressing A-C/EBP failed to respond to myeloid-
specific cytokines, including G-CSF, M-CSF, and IL-5
(Fig. 1 B). On the other hand, they normally responded to
erythropoietin, an erythroid-specific cytokine, and showed
a distinct growth profile in response to GM-CSF as com-
pared with the mock control (Fig. 1 B). GM-CSF is a cy-
tokine that supports cell growth and the differentiation of
all kinds of myeloid cells. In the presence of SCF and GM-
CSF, the transduced cells showed comparable proliferation
with the control at the beginning, but after 1 wk they
stopped growing. Flow cytometric analysis revealed that al-
though the transduced cells failed to develop CD15 gran-
ulocytes and CD14 macrophages, they unexpectedly gave
rise to CD1a CD11b myeloid DCs (Fig. 1 C).
To evaluate the effect of A-C/EBP on myelopoiesis, we
took advantage of well-characterized cell lines. We first
transduced cell lines with GCsam–A-C/EBP–IRES–
Figure 1. Altered differentiation of CD34 progenitors expressing a
dominant-negative C/EBP. (A) The schematic representation of the ret-
roviral vector, GCsam–A-C/EBP–IRES–EGFP, encoding A-C/EBP, a
dominant-negative C/EBP, linked by an IRES to a cDNA encoding
EGFP. The 3 LTR of the vector is replaced with MSCV. , packaging
signal; SD, splice donor; SA, splice acceptor. (B) The effect of A-C/EBP
on the growth of transduced CD34 cells. After transduction, EGFP-pos-
itive cells were selected. Then, cytokine-dependent cell growth was eval-
uated by CFU generated in the presence of indicated cytokines and by
liquid culture in the presence of IL-5 or SCFGM	CSF. To evaluate
IL-5–dependent cell growth, cells were cultured in the presence of SCF,
IL-3, and GM-CSF for the first 5 d to promote the development of eo-
sinophil progenitors. Then, cytokines were replaced to IL-5 alone. Re-
sults are shown as mean  SD of three representative experiments (CFU
assay), or of triplicate cultures (liquid culture). (C) Flow cytometric profiles
of transduced cells cultured for 8 d in the presence of SCF and GM-CSF.
Mock represents the cells transduced with empty vector. Results repre-
sent repeated experiments.
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EGFP, and then EGFP-positive cells were selected by cell
sorting and subjected to in vitro liquid culture. Interest-
ingly, A-C/EBP dramatically inhibited cell proliferation of
myeloid cell lines, U937 (promonocytes), and HL60 (pro-
myelocytes) (Fig. 2 A). In contrast, A-C/EBP did not at all
affect the growth of nonmyeloid cell lines, Jurkat (T cells),
and K562 (erythroid cells) (Fig. 2 A).
Next, we generated U937 cells, stably transfected with
the A-C/EBP cDNA where expression is under the con-
trol of the zinc-inducible human methallothionein pro-
moter, and analyzed the effect of A-C/EBP on U937 cell
differentiation. After treatment with GM-CSF, CD14	
U937 cells differentiate into CD14 monocytes/macro-
phages (Fig. 2 B). However, the expression of A-C/EBP
in U937 cells markedly inhibited monocytic differentia-
tion and promoted an alternative pathway, CD1a DCs
(Fig. 2 B). CD1a cells were also positive for CD11b
and CD11c (unpublished data). These data indicate that
C/EBP transcription factors are essential for the develop-
ment of both granulocytes and macrophages, but not for
DC development.
A Dominant-negative C/EBP Promotes LC Development. DC
differentiation from human CD34 hematopoietic progen-
itor cells can be triggered in vitro by a combination of cy-
tokines consisting of SCF, GM-CSF, and TNF. With
these cytokines, hematopoietic progenitors give rise to two
DC progenitors: CD1aCD14	 progenitor that differenti-
ates into LCs, and CD1a	CD14 monocyte that differenti-
ates into non-LC DCs (17). As shown in Fig. 3 A, CD34
hematopoietic progenitor cells transduced with empty ret-
roviral vector gave rise to DCs differentiated through both
pathways. In contrast, cells expressing A-C/EBP barely
took the pathway through CD14 monocytes, but showed
enhanced DC differentiation from CD1aCD14– progeni-
tors, even in the absence of TNF (Fig. 3 A). Although
there were some variations in DC population ranging at
15%, the characteristic profiles of DCs differentiated
from control and A-C/EBP–expressing cells were always
reproducible. There was no significant difference in DC
morphology with and without A-C/EBP expression (Fig.
3 A). CD14 monocyte-derived DCs and LCs could be
distinguished by the expression of well-characterized cell
surface antigens. E-cadherin is a molecule that is highly ex-
pressed on LCs and is involved in interactions between ke-
ratinocytes and LCs in the epidermis (26). Langerin, a lec-
tin that is specific to LCs, is an endocytic receptor involved
in the induction of Birbeck granule formation (27). DCs
derived from transduced CD34 cells with A-C/EBP were
highly positive for both E-cadherin and Langerin when
compared with control cells (Fig. 3 B), which confirms the
predominant development of LCs with a dominant-nega-
tive C/EBP expression. As is shown in Fig. 3 C, CD34
cells transduced with A-C/EBP, generated a significantly
higher number of CD1a DCs than the mock control in
the absence of TNF. Moreover, even though A-C/EBP
has only additive effects on the total DC number in the
presence of TNF (Fig. 3 C), the absolute LC number is
much higher than the mock control, as judged by the
higher percentages of E-cadherin– and Langerin-positive
LC (Fig. 3 B).
To evaluate the effect of A-C/EBP on LC commitment,
we assessed the frequency of DC colony formation. Trans-
duced CD34 cells were sorted into 96-well plates at 10
cells per well. At day 10, each well was examined individu-
ally by microscopy for the presence of DC colonies consist-
ing of cells with long spiny processes. Under the condition
supplemented with TNF, control cells and A-C/EBP–
expressing cells efficiently formed DC colonies at compara-
ble frequencies (Fig. 3 D). Significantly, A-C/EBP–express-
ing cells exclusively gave rise to DC colonies in 74% of
the wells in the absence of TNF, the condition under
which control cells preferentially formed granulocyte/mac-
rophage colonies, but very few DC colonies (Fig. 3 D).
Figure 2. Growth and differentiation of human myeloid cell lines ex-
pressing a dominant-negative C/EBP. (A) The effect of A-C/EBP on the
growth of human cell lines. After transduction, EGFP-positive cells were
selected by cell sorting, and then subjected to in vitro liquid culture.
Results are shown as mean  SD of triplicate cultures. (B) The effect of
A-C/EBP on the differentiation of a myeloid cell line. Lysates from 2 
105 U937/A-C/EBP cells, either untreated or treated with 100 M
ZnSO4 for 24 h, were separated by SDS-PAGE and immunoblotted with
anti-FLAG antibody (upper panel). U937/A-C/EBP cells were treated
with GM-CSF in the absence or presence of 100 M ZnSO4 for 10 d to
induce differentiation, and then analyzed by flow cytometry (lower
panel). Results represent two independent clones of transfectants.
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These data suggest that CEBP transcription factors are in-
hibitory to LC commitment.
The expression of C/EBP family members in granulo-
cytes and macrophages has been characterized in detail (2).
However, their expression in DCs has not yet been ana-
lyzed. By using RT-PCR, we analyzed mRNA expression
of C/EBP family members (Fig. 3 E). C/EBP members
were expressed weakly in freshly isolated CD34 cells,
with the exception of C/EBP and C/EBP. However,
their mRNA expression was up-regulated in CD14
monocytes, and maintained during DC differentiation in-
duced by GM-CSF and IL-4, although some of them were
down-regulated in activated DCs. In contrast, only
C/EBP and C/EBP were up-regulated during the DC
differentiation from CD34 progenitors. Expression of an-
other myeloid regulator, PU.1, was similarly up-regulated
in both monocytes and DCs.
Function of DCs Expressing a Dominant-negative C/EBP.
Even after the DC commitment, MSCV-driven A-C/EBP
expression is maintained throughout differentiation. Thus,
we analyzed the effects of A-C/EBP on DC maturation
and function. We first checked the expression of func-
tional molecules, including costimulatory molecules CD40,
CD80, and CD86, an activated marker molecule CD83,
and an MHC class II molecule, HLA-DR (Fig. 4 A). DCs
with A-C/EBP expressed significant levels of functional
molecules even in the absence of TNF, and expressed
comparable or even higher levels of functional molecules
Figure 3. Promoted LC com-
mitment in CD34 progenitors
expressing a dominant-negative
C/EBP. (A) DC differentiation
of CD34 progenitors trans-
duced with A-C/EBP. After
transduction, EGFP-positive
cells were selected and cultured
for the indicated days either with
or without TNF, in addition
to basic cytokines, SCF, and
GM-CSF. Expression of CD1a
and CD14 cell surface antigens
were analyzed by flow cytome-
try. At day 10, CD1a cells were
collected by cell sorting and
processed for May-Grüenwald
Giemsa staining. (B) Flow cyto-
metric profiles of transduced
CD34 progenitors cultured for
10 d either with or without
TNF, in addition to SCF and
GM-CSF. CD14 monocytes
were cultured for 10 d in the
presence of GM-CSF and IL-4,
and treated with TNF for the
last 3 d, and then similarly pro-
cessed as a control. (C) The effect
of A-C/EBP on DC develop-
ment from transduced CD34
cells. After transduction, EGFP-
positive cells were selected and
cultured in the presence of indi-
cated cytokines. The absolute
cell number of CD1a DCs
(right panel) was calculated from
the percentage of CD1a cells
detected by FACS® analysis. Re-
sults are shown as mean  SD
of triplicate cultures. (D) The
plating efficiency of transduced
CD34 cells to give rise to DC
colonies. Transduced CD34
cells were sorted into 96-well
plates at 10 cells per well and cultured for 10 d with the indicated cytokines. DC colonies consisting of more than 100 cells and of 20–100 cells were de-
fined as large and small colonies, respectively. Results are shown as mean  SD of triplicate cultures. A-C/E represents A-C/EBP (E) The expression of
human C/EBP family. RT-PCR was performed on normalized cDNA templates. PCR products were electrophoresed on agarose gels and visualized by
ethidium bromide staining. Cord blood CD34 cells (CD34) and peripheral blood CD14 monocytes (CD14 monocytes) were collected by cell sort-
ing. Peripheral blood CD14 monocytes were cultured for 10 d in the presence of GM-CSF and IL-4, either without (CD14-derived DC) or with
TNF, for the last 3 d (activated DC), and then CD1a DCs were collected by cell sorting. Cord blood CD34 cells were cultured in the presence of
SCF, GM-CSF, and TNF for 14 d, and then CD1a DCs were collected by cell sorting (CD34-derived DC). Lane H2O represents the negative control
without template.
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than control cells. We then studied the T cell stimulatory
capacity of DCs with A-C/EBP in the allogenic MLR
(Fig. 4 B). Considering the advanced maturation status of
the A-C/EBP–transduced DCs, we expected that they be-
have normally in function. However, they showed a lim-
ited capacity in stimulating T cell proliferation. Although
the addition of TNF in culture increased their stimula-
tory capacity, their capacity was always lower than the
controls. During the MLR, DCs with A-C/EBP were
prone to die from apoptosis earlier than the control cells
(unpublished data).
C/EBP Facilitates Granulocytic Differentiation. The effects
of C/EBP family members on myeloid differentiation are
evident with C/EBP, C/EBP, and C/EBP. Knockout
mice of C/EBP and C/EBP genes show a selective
block in the differentiation of granulocytes (11) and the
impaired terminal differentiation of neutrophils (12), re-
spectively. In addition, the forced expression of either
C/EBP or C/EBP induces eosinophilic differentiation
of a multipotent chicken progenitor cell line, MEF (28),
and of C/EBP it induces a neutrophilic differentiation of
a bipotential human myeloid cell line, U937 (29). How-
ever, no evidence has been reported that demonstrates the
instructive effects of C/EBP transcription factors on the
differentiation of primary hematopoietic cells.
To confirm their effects on myeloid differentiation, we
transduced CD34 progenitor cells with either C/EBP or
C/EBP and then cultured cells in the presence of SCF
and GM-CSF (Fig. 5 A). As expected, transduced cells
showed enhanced development of CD15 granulocytes.
Among granulocytes, eosinophils preferentially developed,
which were positive for EPO (57% and 52% of total cells
with C/EBP and C/EBP, respectively) and showed IL-
5–dependent cell growth (Fig. 5 B). In addition, neutrophil
maturation was markedly promoted as judged by the nu-
clear segmentation, although the neutrophil population was
Figure 4. Maturation and
function of DCs derived from
transduced CD34 cells with
A-C/EBP. (A) Flow cytometric
profiles of transduced CD34
progenitors cultured for 10 d ei-
ther with or without TNF, in
addition to SCF and GM-CSF.
(B) Allogenic T cell proliferation
stimulated by cells generated
from transduced CD34 cells.
CD34 cells transduced with in-
dicated retrovirus were cultured
with indicated cytokines for 10 d
(stimulator). A constant number
of 105 allogenic CD4 T cells (re-
sponder) were incubated with graded numbers of irradiated (3,000 rad, 137Cs source) stimulators. Proliferation of T cells was monitored by measuring
bromodeoxyuridine incorporation after 4 d of culture. Results are shown as mean  SD of triplicate cultures.
Figure 5. C/EBP promotes granulocytic differentiation and inhibits DC differentiation. (A) Promoted granulocytic differentiation of CD34 cells
transduced with wild-type C/EBP. CD34 progenitors transduced with either C/EBP or C/EBP were cultured for 10 d in the presence of SCF and
GM-CSF, and then analyzed by flow cytometry, May-Grüenwald Giemsa staining, and immunostaining for intracytoplasmic EPO. Arrows indicate neu-
trophils with advanced differentiation. (B) The effect of C/EBP expression on the IL-5–dependent cell growth. After transduction, cells were cultured in
the presence of SCF and GM-CSF for 3 d. Then, cytokines were replaced to IL-5 alone. Results are shown as mean  SD of triplicate cultures. (C) The
inhibited DC differentiation of CD34 progenitors transduced with wild-type C/EBP. CD34 progenitors transduced with either C/EBP or C/EBP
were cultured for 10 d in the presence of SCF, GM-CSF, and TNF, and then analyzed by flow cytometry.
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much lower than eosinophils. In contrast, monocytic dif-
ferentiation was partially suppressed, but a significant num-
ber of CD14 monocytes/macrophages still developed.
Next, we analyzed the function of C/EBP and
C/EBP with respect to their ability to inhibit DC differ-
entiation. Given the strong promoting effect of a domi-
nant-negative C/EBP on LC differentiation, it is easy to
speculate that C/EBP transcription factors function as neg-
ative regulators in this process. Enforced expression of
C/EBP or C/EBP in CD34 progenitor cells com-
pletely inhibited TNF-induced DC differentiation of
both LC and DC derived from CD14 monocytes (Fig. 5
C), and instead induced differentiation of CD15 granulo-
cytes, leaving a significant number of CD14 monocytes/
macrophages still developed. These findings confirm the
inhibitory effect of C/EBP transcription factors in LC de-
velopment, as well as raise the possibility that C/EBP in-
hibits the differentiation of monocytes into DCs.
C/EBP Cancels DC Differentiation Induced by PU.1. In
search of transcription factors that positively regulate DC
differentiation, we identified that PU.1 facilitates DC dif-
ferentiation. CD34 cells transduced with PU.1 preferen-
tially differentiated into DCs without TNF (Fig. 6 A).
The majority of DCs induced by PU.1 were positive for
E-cadherin and Langerin, suggesting that PU.1 promotes
the development of LC-type DC. In addition, PU.1 showed
comparable capacity to A-C/EBP in terms of DC commit-
ment in the absence of TNF (Fig. 6 B). These data estab-
lish PU.1 and C/EBP as positive and negative regulators
for LC commitment, respectively.
To analyze the functional interaction between the two
factors, we cotransduced CD34 cells with both PU.1 and
C/EBP and then cultured cells in the absence of TNF. As
was the case with TNF, both C/EBP and C/EBP
completely inhibited DC differentiation induced by PU.1
(Fig. 7 A). Next, to localize the C/EBP domain responsi-
ble for the inhibition of DC development, we generated
C/EBP mutants that lack either basic leucine zipper do-
main or NH2-terminal transactivation domain. Although
the mutants were expressed at the same levels as wild-type
C/EBP (unpublished data), they failed to inhibit DC dif-
ferentiation induced by both PU.1 and TNF (Fig. 7 B),
indicating that both domains are essential to inhibit DC de-
velopment. We further analyzed the mRNA expression of
C/EBPs and PU.1 in transduced cells by RT-PCR (Fig. 7
C). At the mRNA levels, however, we could not detect
any direct effects on endogenous C/EBP and PU.1 expres-
sion by exogenous gene expression.
Discussion
Pluripotent myeloid progenitor cells give rise to progen-
itors for granulocytes/macrophages (CFU-GM/eosinophil
[Eo]) and LC-type DCs (Fig. 8). In this study, we showed
that myeloid progenitor cells expressing a dominant-nega-
tive C/EBP differentiate exclusively into LCs (Figs. 1 and
3). Even the U937 cell line, which has never been known
to differentiate into DCs, showed DC differentiation when
the A-C/EBP expression was induced (Fig. 2 B). As is
clearly shown in Fig. 3 D, A-C/EBP strongly affected the
lineage commitment of myeloid progenitor cells, and
switched the myeloid progenitor cell fate from granulo-
cytes/macrophages into LCs. Its effect on the lineage com-
mitment is comparable with that of TNF, a strong DC
inducer. Conversely, the expression of wild-type C/EBP
inhibited LC commitment induced by TNF, and pro-
moted granulocyte/macrophage differentiation (Fig. 5 C).
These data indicate that C/EBP family is essential to com-
mit myeloid progenitor cells to granulocyte/macrophage
lineage. On the contrary, C/EBP family acts as a negative
regulator for the commitment of LCs.
In search of transcription factors that positively regulate
LC development, we identified that PU.1 facilitates LC de-
velopment. PU.1 promoted LC commitment of CD34
progenitor cells (Fig. 6). Moreover, LC commitment in-
duced by PU.1 was completely inhibited by coexpressed
wild-type C/EBP (Fig. 7 A). These data not only suggest
that PU.1 is one of the positive regulators that drive LC
commitment, but also support our finding that C/EBP
family acts as a negative regulator for this process. These
findings contrast with the requirement of both PU.1 and
C/EBP in the development of granulocytes and macro-
phages, and suggest that dosage balance between the two
regulators is the crucial determinant for LC commitment in
Figure 6. PU.1 promotes LC commitment in CD34 progenitors. (A)
PU.1 promotes LC differentiation. CD34 progenitors transduced with
PU.1 were cultured for 10 d in the presence of SCF and GM-CSF, and
then analyzed by flow cytometry for cell surface antigen expression. (B)
Plating efficiency of transduced CD34 cells to give rise to DC colonies.
Transduced CD34 cells with the indicated retrovirus were sorted into
96-well plates at 10 cells per well and cultured for 10 d with the indicated
cytokines. DC colonies consisting of more than 100 cells and of 20–100
cells were defined as large and small colonies, respectively. Results are
shown as mean  SD of triplicate cultures. A-C/E represents A-C/EBP.
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pluripotent myeloid progenitor cells. We have recently
found that C/EBP physically interacts with PU.1 through
its bZIP region, and displaces c-Jun, a coactivator of PU.1
(30) from binding to PU.1, resulting in the suppression of
PU.1 transactivation (unpublished data). We expected that
this kind of interaction might happen in the commit-
ment of pluripotent myeloid progenitor cells. However,
C/EBP 
AD mutant that retains bZIP domain failed to
inhibit LC differentiation induced by PU.1 and TNF
(Fig. 7 B). 
bZIP mutant also did not inhibit. These data
indicate that the intact form of C/EBP is essential to inhibit
LC differentiation. Moreover, we could not detect any di-
rect effects on endogenous mRNA expression of C/EBP
and PU.1 by exogenous A-C/EBP or PU.1 (Fig. 7 C).
Nevertheless, these data do not necessarily deny the possi-
ble cross talk between C/EBP and PU.1. Detailed analysis
is needed to precisely understand the possible interplay be-
tween the two regulators in LC commitment. Additionally,
it is also possible that either the C/EBP and PU.1 are direct
downstream targets of TNF, or they have functional cross
talks with downstream targets of TNF, such as NFB.
The roles of C/EBP and PU.1 in TNF-signaling cascade
also remain to be resolved. Reciprocal interactions of the
two transcription factors have been reported to determine
erythroid versus myeloid cells (GATA-1 vs. PU.1) (31, 32)
and distinct pituitary cell types (Pit-1 vs. GATA-2) (33).
Such a mechanism may also operate in a number of other
cell types. Further analysis will help our understanding of
the regulatory mechanism of lineage commitment involv-
ing multiple transcription factors.
A-C/EBP not only promoted DC commitment, but also
DC maturation of transduced CD34 progenitor cells.
Transduced cells rapidly differentiated into mature DCs
(Fig. 3 A) and the expression levels of functional molecules
were mostly higher in cells with A-C/EBP rather than in
the control cells (Fig. 4 A). These findings suggest that
C/EBP transcription factors are not necessary for DC mat-
uration and function. However, DCs with A-C/EBP showed
limited capacity of T cell stimulation in the allogenic
MLR. Given the mRNA expression of several C/EBP
members in DCs (Fig. 3 E), C/EBP transcription factors
seem to have implications in DC function. In many tissues
and cells, C/EBP and C/EBP are strongly up-regulated
Figure 7. Reciprocal roles for C/EBP and PU.1 in the development of
LCs. (A) The inhibition of PU.1-dependent LC differentiation by cotrans-
duced wild-type C/EBP. CD34 progenitors cotransduced with PU.1 and
either C/EBP or C/EBP were cultured for 10 d in the presence of SCF
and GM-CSF. Then, CD1a expression was analyzed by flow cytometry.
(B) The effects of C/EBP mutants on DC differentiation. Schematic rep-
resentation of C/EBP mutants (upper panel). TE, transactivation ele-
ment; N, nuclear localization signal. CD34 progenitors cotransduced
with PU.1 and C/EBP mutants were cultured for 10 d in the presence of
SCF and GM-CSF only (middle panel). CD34 progenitors that only
transduced with C/EBP mutants were similarly processed in the presence
of SCF, GM-CSF, and TNF (lower panel). Then, CD1a expression was
analyzed by flow cytometry. (C) RNA expression of endogenous C/EBP
and PU.1 in transduced cells by RT-PCR. Cord blood CD34 cells
(CD34) were collected by cell sorting. Cord blood CD34 cells trans-
duced with empty vector (mock) were cultured for 10 d in the presence of
SCF, GM-CSF, and TNF. Cord blood CD34 cells transduced with ei-
ther with A-C/EBP or PU.1 were similarly processed in the presence of
SCF and GM-CSF only. Then, CD1a DCs were collected by cell sort-
ing. Lane H2O represents the negative control without template.
Figure 8. Model for the role of C/EBP and PU.1 in lineage commit-
ment. As explained in the text, C/EBP activity is essential for the commit-
ment of pluripotent myeloid progenitors into granulocyte/macrophage
lineage. With impaired C/EBP function, pluripotent myeloid progenitors
take an alternative differentiation pathway of LC. On the other hand, the
enforced expression of PU.1 in pluripotent myeloid progenitor cells pro-
motes LC commitment, whereas that of C/EBP promotes granulocytic
differentiation and inhibits PU.1-induced LC commitment. These find-
ings suggest that the lineage commitment of pluripotent myeloid progeni-
tor cells is mediated by functional balance between PU.1 and C/EBP tran-
scription factors. Eo, eosinophils; Neu, neutrophils; Macro, macrophages.
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at the transcriptional level by inflammatory stimuli such as
bacterial lipopolysaccharide, and by cytokines such as IL-6,
IL-1, and TNF (34). It is possible that C/EBP members
are up-regulated in activated DCs and play a role in regu-
lating DC function, as C/EBP has indispensable roles in
the regulation of macrophage function (13). Further analy-
sis is needed to determine the role of C/EBP transcription
factors in DC function.
C/EBP transcription factors are essential for granulo-
cytic and monocytic development. Pluripotent myeloid
progenitor cells diverse into a number of myeloid proge-
nies with distinct functions. PU.1 is expressed throughout
myeloid lineage and is a master regulator involved in the
development and function of all myeloid progenies (2). On
the other hand, C/EBP family transcription factors have
been shown to cooperate with PU.1 in transactivating pro-
moters that are specific to granulocytes/macrophages (2).
Impaired granulocytic differentiation is evident in mice de-
ficient in the C/EBP and C/EBP gene, which suggests
the indispensable function of these two family members in
supporting granulocytic differentiation. In contrast, single-
gene knockout mice of C/EBP family genes have not
shown impaired macrophage differentiation (9), suggesting
a functional redundancy among C/EBP members in sup-
porting macrophage differentiation. By using a dominant-
negative C/EBP, we clearly demonstrated the essential
role of C/EBP transcription factors in the development of
macrophages and granulocytes. As shown in Fig. 1,
A-C/EBP inhibited granulocyte/macrophage develop-
ment from transduced CD34 progenitor cells. In addi-
tion, A-C/EBP inhibited monocytic differentiation of an
immature myeloid cell line, U937 (Fig. 2 B). In these ex-
periments, however, A-C/EBP caused lineage switch into
DCs rather than complete differentiation block. Thus,
these data underscore the critical role of C/EBP transcrip-
tion factors in the commitment of pluripotent myeloid
progenitor cells into granulocyte/macrophage lineage (Fig.
8). Their roles in later stages of monocytic differentiation
remain to be determined.
With regard to the instructive ability of C/EBP tran-
scription factors to drive granulocytic differentiation, most
of the evidence has been based on the use of cell lines in
the experiments. We have presented the first evidence of
C/EBP transcription factors driving granulocytic differenti-
ation of primary hematopoietic cells (Fig. 5). CD34 cells
transduced either with C/EBP or C/EBP, preferentially
developed into eosinophils. C/EBP and C/EBP have
been implicated in the development of eosinophils in co-
operation with GATA-1 (35, 36). Our data suggest that
C/EBP overload is enough to drive eosinophilic commit-
ment in myeloid progenitor cells. Eosinophils develop from
the committed myeloid progenitor cells (CFU-GM/Eo)
along with CFU-GM (Fig. 8). The expression level of
C/EBP in combination with GATA-1 could be the critical
determinant for lineage commitment in the committed
myeloid progenitor cells. Moreover, although the neutro-
phil population was much lower than eosinophils, neutro-
phil differentiation and maturation were markedly acceler-
ated with wild-type C/EBP (Fig. 5). This finding confirms
our previous observation that the enforced expression of
C/EBP in a bipotential human myeloid cell line promotes
neutrophilic differentiation (29). Taken together, our find-
ings suggest that C/EBP transcription factors play a role in
each cell commitment throughout myeloid development,
and regulate diversification of the myeloid system (Fig. 8).
Transcriptional regulation of myeloid DC development
is largely unknown. In mice, CD8	 myeloid DCs are
missing in mice with a dominant-negative mutation of
Ikaros gene, and in RelB knockout mice (20, 21). How-
ever, these mutant mice still retain LC development, sup-
porting specialized development of LCs from bone marrow
progenitor cells. In this study, we presented the first
evidence of transcriptional regulation governing LC de-
velopment. The positive regulator, PU.1, is a potential
downstream player for TNF, a strong inducer of DC de-
velopment. Several cytokines other than TNF are known
to support DC development including GM-CSF, TGF,
and Flt-3 ligand (37, 38). We expect to further understand
transcriptional regulation of DC development by identify-
ing downstream transcription factors of these cytokines.
DCs are major target cells for therapeutic approaches to al-
lergy, autoimmune disease, infectious disease, and cancer.
We propose that modulating transcription factors in my-
eloid progenitor cells would be a new approach to manipu-
late DC development and effector functions in vivo. Our
approach will provide useful information to therapeutic
manipulation of the immune system.
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